South San Francisco, CA, July 20, 2020 – FlemingMartin is pleased to announce that RAPT Therapeutics (NASDAQ: RAPT), an immunology-based biopharmaceutical company dedicated to conquering cancer and inflammatory diseases via best-in-class oral therapies, has hired Phyllis Loud Gray as their Vice President of Human Resources. Phyllis will serve on the executive leadership team and help steer the people strategy, HR operations, and future growth of this ascending organization.
Over her impressive career in the Life Sciences, Phyllis has served as a key leader and strategic business partner advising on the full spectrum of Human Resources responsibilities. For the past 3 years, Phyllis directed the Human Resources function at Sunesis Pharmaceuticals (NASDAQ: SNSS), a company focused on treating solid and hematologic cancers. Prior to Sunesis, Phyllis drove HR strategy and execution for Crescendo Bioscience (a Myriad Company), Ingenuity Systems (acquired by QIAGEN), VisX (acquired by Advanced Medical Optics), and the Syva Company. Phyllis received her B.S.B.A from California State University, East Bay.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing a proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases.
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms and CEOs of companies to build successful execution-focused management teams. FlemingMartin focuses in the Technology, Manufacturing, and Consumer Products & Services industries. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.